重症患者凝血酶原复合物合理应用中国专家共识  

Chinese expert consensus on the rational use of prothrombin complex concentrate in critically ill patients

作　　者：宋景春 王岗[2] 房云海[3] 吴海鹰[4] 尹海燕 张进华 柯路 丁仁彧[8] 周洲 中国医药教育协会血栓与止血危重病专业委员会 全军重症医学专业委员会 中国研究型医院学会血栓与止血专业委员会 Song Jing-Chun;Wang Gang;Fang Yun-Hai;Wu Hai-Ying;Yin Hai-Yan;Zhang Jin-Hua;Ke-Lu;Ding Ren-Yu;Zhou Zhou;Chinese Society of Thrombosis,Hemostasis and Critical Care,Chinese Medicine Education Association;People's Liberation Army Professional Committee of Critical Care Medicine;Chinese Society of Thrombosis and Hemostasis,Chinese Research Hospital Association(Department of Critical Care Medicine,the 908th Hospital of Joint Logistics Support Forces of Chinese PLA,Nanchang,Jiangxi 330002,China;Department of Critical Care Medicine,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi 710004,China;Hemophilia Diagnosis and Treatment Center,Shandong Blood Center,Jinan,Shandong 250013,China;Emergency Department,the First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650032,China;Department of Critical Care Medicine,the First Affiliated Hospital of Jinan University,Guangzhou,Guangdong 510630,China;Pharmacy Department,Fujian Provincial Maternity and Child Health Hospital,Fuzhou,Fujian 350005,China;Department of Critical Care Medicine,General Hospital of Eastern Theater Command,Nanjing,Jiangsu 210002,China;Department of Critical Care Medicine,the First Affiliated Hospital of Chinese Medical University,Shenyang,Liaoning 110001,China;Department of Laboratory Medicine,Fuwai Hospital,Chinese Academy of Medical Sciences,Beijing 100037,China;不详)

机构地区：[1]解放军联勤保障部队第908医院重症医学科,江西南昌330002 [2]西安交通大学第二附属医院重症医学科,陕西西安710004 [3]山东省血液中心血友病诊疗中心,山东济南250013 [4]昆明医科大学第一附属医院急诊科,云南昆明650032 [5]暨南大学附属第一医院重症医学科,广东广州510630 [6]福建省妇幼保健院药学科,福建福州350005 [7]东部战区总医院重症医学科,江苏南京210002 [8]中国医科大学附属第一医院重症医学科,辽宁沈阳110001 [9]中国医学科学院阜外医院检验科,北京100037 [10]不详

出　　处：《解放军医学杂志》2023年第12期1359-1369,共11页Medical Journal of Chinese People's Liberation Army

摘　　要：凝血酶原复合物(PCC)是以维生素K依赖性凝血因子为主要成分的血液制品。虽然PCC已在临床应用70多年,安全性已得到明显提升,且已经广泛应用于重症患者凝血功能障碍或大出血的治疗,但若使用方法不当,可能会减弱止血效果或增加血栓形成的风险。为了规范PCC的合理使用,中国医药教育协会血栓与止血危重病专业委员会、全军重症医学专业委员会及中国研究型医院学会血栓与止血专业委员会组织制定此专家共识,包括定义、适应证、监测与评价等3个部分,共10条建议,旨在帮助临床医师合理使用PCC,以提高重症患者救治水平。The prothrombin complex concentrate(PCC)is a blood product that mainly contains vitamin K-dependent coagulation factors.PCC has been used clinically for more than 70 years,and its safety has been significantly improved.It has been widely used in the treatment of coagulation disorders or severe bleeding in critically ill patients.If used improperly,it may weaken the hemostatic effect or increase the risk of thrombosis.In order to standardize the rational use of PCC,Chinese Society of Thrombosis,Hemostasis and Critical Care,Chinese Medicine Education Association,People's Liberation Army Professional Committee of Critical Care Medicine,Chinese Society of Thrombosis and Hemostasis,Chinese Research Hospital Association have organized the formulation of this expert consensus,including three parts:definition,indications,and monitoring and evaluation of efficacy,with a total of 10 suggestions,aiming to help clinicians reasonably use PCC and improve the treatment in critical illness.

关 键 词：凝血酶原复合物 血液凝固因子 危重病 出血 

分 类 号：R459.7[医药卫生—急诊医学]